A Phase 3b, Randomized, Open Label, Feasibility Study of a Single Priming Dose of Meningococcal Group C Conjugate Vaccine (NeisVac-C) in Infants.

Trial Profile

A Phase 3b, Randomized, Open Label, Feasibility Study of a Single Priming Dose of Meningococcal Group C Conjugate Vaccine (NeisVac-C) in Infants.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 May 2015

At a glance

  • Drugs Meningococcal vaccine group C conjugate (Primary) ; Hib-DTaP-hepatitis B-poliovirus vaccine
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal infections; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Baxter Healthcare Corporation
  • Most Recent Events

    • 11 May 2013 Results published in Vaccine.
    • 11 Jul 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Primary endpoint 'Seroprotection-rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top